文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

无创呼吸支持与接受机械通气的脑损伤患者拔管结局的关联:ENIO前瞻性观察研究的二次分析

Association of Noninvasive Respiratory Support with Extubation Outcomes in Brain-injured Patients Receiving Mechanical Ventilation: A Secondary Analysis of the ENIO Prospective Observational Study.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01
一句话结论在脑损伤拔管患者中,预防性使用经鼻高流量氧疗或无创正压通气均与再插管风险降低无显著关联,需前瞻性试验确认。

该研究为ENIO前瞻性观察研究的二次分析,纳入62家医院、19个国家的1115例接受机械通气的急性脑损伤患者,其中267例(23.9%)拔管后接受经鼻高流量氧疗或无创正压通气。采用混合效应logistic回归模型(患者层面协变量,医院和国家随机截距)评估预防性无创呼吸支持与ICU期间再插管的关联。结果显示,与常规氧疗相比,预防性经鼻高流量氧疗(OR 0.97,95%CI 0.54-1.73)和无创正压通气(OR 0.63,95%CI 0.30-1.32)均与再插管风险降低无显著关联,敏感性分析和贝叶斯分析结果一致。作者认为,该人群预防性使用上述支持与再插管无关,需前瞻性试验确认疗效。

要点

  • 在1115例急性脑损伤拔管患者中,预防性经鼻高流量氧疗与再插管无显著关联(OR 0.97,95%CI 0.54-1.73)。
  • 预防性无创正压通气与再插管亦无显著关联(OR 0.63,95%CI 0.30-1.32)。
  • 267例(23.9%)拔管后接受经鼻高流量氧疗或无创正压通气,与常规氧疗相比未见再插管风险降低。
  • 敏感性分析(替代调整方案、缺失数据、更短终点时间窗、竞争风险)结果与主分析一致。
  • 贝叶斯分析中,经鼻高流量氧疗降低再插管的概率为17%-34%,无创正压通气为46%-74%。

适用人群与场景

  • 接受机械通气并拔管的急性脑损伤患者,来自62家医院、19个国家的前瞻性观察研究队列。
  • 二次分析纳入1115例患者,其中267例(23.9%)拔管后接受经鼻高流量氧疗或无创正压通气。

处置流程与药物剂量

  • 预防性(即计划性)拔管后使用经鼻高流量氧疗或无创正压通气,与常规氧疗进行比较;原文未给出具体参数、剂量或疗程。

研究设计与关键结果

  • 研究类型:前瞻性观察研究(ENIO,NCT03400904)的二次分析;纳入1115例急性脑损伤机械通气拔管患者,来自62家医院、19个国家。
  • 主要终点为ICU期间再插管;267例(23.9%)接受预防性经鼻高流量氧疗或无创正压通气。
  • 与常规氧疗相比,预防性经鼻高流量氧疗与再插管无显著关联(OR 0.97,95%CI 0.54-1.73)。
  • 与常规氧疗相比,预防性无创正压通气与再插管无显著关联(OR 0.63,95%CI 0.30-1.32)。
  • 敏感性分析(替代调整方案、缺失数据、更短终点时间窗、竞争风险)结果一致。
  • 贝叶斯分析(怀疑先验和数据驱动先验)中,经鼻高流量氧疗降低再插管的概率为17%-34%,无创正压通气为46%-74%。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究的二次分析。
  • 局限:原文未报告局限性;作者在结论中提出需前瞻性试验确认该人群的治疗效应。

对床旁实践的改变

  • 作者认为,在急性脑损伤拔管患者中,预防性使用经鼻高流量氧疗或无创正压通气与再插管无关;该结果不改变常规氧疗作为对照的地位,原文未据此给出推荐。

指南或共识出处

  • ENIO前瞻性观察研究(clinicaltrials.gov NCT03400904)的二次分析,发表于Am J Respir Crit Care Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Noninvasive respiratory support using a high-flow nasal cannula (HFNC) or noninvasive positive pressure ventilation (NIPPV) can decrease the risk of reintubation in patients being liberated from mechanical ventilation, but effects in patients with acute brain injury (ABI) are unknown. Objectives: To evaluate the association between postextubation noninvasive respiratory support and reintubation in patients with ABI being liberated from mechanical ventilation. Methods: This was a secondary analysis of a prospective, observational study of mechanically ventilated patients with ABI (clinicaltrials.gov identifier NCT03400904). The primary endpoint was reintubation during ICU admission. We used mixed-effects logistic regression models with patient-level covariates and random intercepts for hospital and country to evaluate the association between prophylactic (i.e., planned) HFNC or NIPPV and reintubation. Measurements and Main Results: 1,115 patients were included from 62 hospitals and 19 countries, of whom 267 received HFNC or NIPPV following extubation (23.9%). Compared with conventional oxygen therapy, neither prophylactic HFNC nor NIPPV was associated with decreased odds of reintubation (respectively, odds ratios of 0.97 [95% confidence interval, 0.54-1.73] and 0.63 [0.30-1.32]). Findings remained consistent in sensitivity analyses accounting for alternate adjustment procedures, missing data, shorter time frames of the primary endpoint, and competing risks precluding reintubation. In a Bayesian analysis using skeptical and data-driven priors, the probabilities of reduced reintubation ranged from 17% to 34% for HFNC and from 46% to 74% for NIPPV. Conclusions: In a large cohort of brain-injured patients undergoing liberation from mechanical ventilation, prophylactic use of HFNC and NIPPV were not associated with reintubation. Prospective trials are needed to confirm treatment effects in this population. Primary study registered with www.clinicaltrials.gov (NCT03400904).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Taran S, Diaz-Cruz C, Perrot B, et al. Association of Noninvasive Respiratory Support with Extubation Outcomes in Brain-injured Patients Receiving Mechanical Ventilation: A Secondary Analysis of the ENIO Prospective Observational Study. Am J Respir Crit Care Med. 2023. PMID: 37192445. doi:10.1164/rccm.202212-2249OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。